Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13763)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 7, 2017 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Asghar K, Farooq A, Zulfiqar B, Rashid MU. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World J Gastroenterol 2017; 23(13): 2286-2293 [PMID: 28428708 DOI: 10.3748/wjg.v23.i13.2286] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i13/2286.htm |
| Number | Citing Articles |
| 1 |
Atsunori Tsuchiya, Masahiro Ogawa, Takayuki Watanabe, Suguru Takeuchi, Yuichi Kojima, Yusuke Watanabe, Naruhiro Kimura, Kazunao Hayashi, Junji Yokoyama, Shuji Terai. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019; 5(3): e01325 doi: 10.1016/j.heliyon.2019.e01325
|
| 2 |
Thomas T DeLeon, Yumei Zhou, Bolni M Nagalo, Raquel T Yokoda, Daniel H Ahn, Ramesh K Ramanathan, Marcela A Salomao, Bashar A Aqel, Amit Mahipal, Tanios S Bekaii-Saab, Mitesh J Borad. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy 2018; 10(12): 1077 doi: 10.2217/imt-2018-0024
|
| 3 |
Sulbha K. Sharma, Michael R. Hamblin. Cancer Immunology. 2021; : 383 doi: 10.1007/978-3-030-50287-4_21
|
| 4 |
Miaoqing Wu, Xiaoliang Wu, Xing Wang, Xiangchan Hong, Yifan Liu, Guangzhao Lv, Cong Li, Zhizhong Pan, Rongxin Zhang, Gong Chen. IDO1/COX2 Expression Is Associated with Poor Prognosis in Colorectal Cancer Liver Oligometastases. Journal of Personalized Medicine 2023; 13(3): 496 doi: 10.3390/jpm13030496
|
| 5 |
Jian Xue, Hongbo Ni, Fan Wang, Ke Xu, Meng Niu. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. Journal of Interventional Medicine 2021; 4(3): 105 doi: 10.1016/j.jimed.2021.05.002
|
| 6 |
Lu Sun, Zhixian Guo, Jihong Sun, Jingjing Li, Zihui Dong, Yize Zhang, Jianan Chen, Quancheng Kan, Zujiang Yu. MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway. Biomedicine & Pharmacotherapy 2018; 107: 168 doi: 10.1016/j.biopha.2018.07.151
|
| 7 |
Yinnan Meng, Wei Wang, Meng Chen, Kuifei Chen, Xinhang Xia, Suna Zhou, Haihua Yang. GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer. Frontiers in Immunology 2021; 11 doi: 10.3389/fimmu.2020.622467
|
| 8 |
Debanjan Sarkar, Sankar Bhattacharyya. Phospholipases in Physiology and Pathology. 2023; : 111 doi: 10.1016/B978-0-323-95698-7.00021-8
|
| 9 |
Yun Hua Lee, David Tai, Connie Yip, Su Pin Choo, Valerie Chew. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.568759
|
| 10 |
Lingyan Xu, Jiawei Ling, Chang Su, Yu-Wen Su, Yan Xu, Zhenzhou Jiang. Emerging Roles on Immunological Effect of Indoleamine 2,3-Dioxygenase in Liver Injuries. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.756435
|
| 11 |
Tim F. Greten, Chunwei Walter Lai, Guangfu Li, Kevin F. Staveley-O’Carroll. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology 2019; 156(2): 510 doi: 10.1053/j.gastro.2018.09.051
|
| 12 |
Elisabetta Cariani, Gabriele Missale. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International 2019; 39(9): 1608 doi: 10.1111/liv.14192
|
| 13 |
Saranya Chidambaranathan Reghupaty, Devanand Sarkar. Current Status of Gene Therapy in Hepatocellular Carcinoma. Cancers 2019; 11(9): 1265 doi: 10.3390/cancers11091265
|
| 14 |
Tiantian Qiu, Donghua Li, Yu Liu, Hui Ren, Xuan Yang, Wenting Luo. Astragaloside IV Inhibits the Proliferation of Human Uterine Leiomyomas by Targeting IDO1. Cancers 2022; 14(18): 4424 doi: 10.3390/cancers14184424
|
| 15 |
Kashif Asghar, Shaarif Bashir, Iftikhar Ali Rana, Muhammad Abu Bakar, Asim Farooq, Muhammad Hassan, Zukhruf Asif, Mahnoor Afzal, Iqra Masood, Muhammad Ishaq, Muhammad Tahseen, Sundus Bilal, Shafqat Mehmood, Nosheen Kanwal, Islah Ud Din, Asif Loya. PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients. Journal of Hepatocellular Carcinoma 2023; : 921 doi: 10.2147/JHC.S409741
|
| 16 |
Ruonan Yang, Nan Gao, Qian Chang, Xianchun Meng, Wanhai Wang. The role of IDO, IL‐10, and TGF‐β in the HCV‐associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Journal of Medical Virology 2019; 91(2): 265 doi: 10.1002/jmv.25083
|
| 17 |
Federica Finetti, Cristina Travelli, Jasmine Ercoli, Giorgia Colombo, Erica Buoso, Lorenza Trabalzini. Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity. Biology 2020; 9(12): 434 doi: 10.3390/biology9120434
|
| 18 |
Jeong-Yeon Mun, Sun-Hee Leem, Jun Ho Lee, Hyuk Soon Kim. Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.864739
|
| 19 |
Aline Talhouk, Heather Derocher, Pascal Schmidt, Samuel Leung, Katy Milne, C. Blake Gilks, Michael S. Anglesio, Brad H. Nelson, Jessica N. McAlpine. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clinical Cancer Research 2019; 25(8): 2537 doi: 10.1158/1078-0432.CCR-18-3241
|
| 20 |
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology 2022; 86: 799 doi: 10.1016/j.semcancer.2022.01.005
|
| 21 |
Chih-Ta Chen, Pei-Hua Wu, Chia-Chi Hu, Hsiao-Ching Nien, Jin-Town Wang, Jin-Chuan Sheu, Lu-Ping Chow. Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling. International Journal of Molecular Sciences 2021; 22(21): 11661 doi: 10.3390/ijms222111661
|